Brief: Senti Biosciences Q4 Net Income USD -18.716 Million
21/03/2024 20:06
Mar 21 (Reuters) - Senti Biosciences Q4 operating income USD -18.698 million. * Q4 basic EPS USD -0.42 * Q4 operating expenses USD 18.698 million * Q4 EPS USD -0.42
Recent news on Senti Biosciences Holdings
See all newsBrief: Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder
Senti Biosciences Q1 net loss narrows on cost reduction
Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy
Brief: Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing
Senti Biosciences Q4 revenue misses analyst estimates